GoodRx (GDRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Definitive additional proxy materials filed regarding upcoming shareholder meeting.
Filing confirms no fee required for submission under current SEC rules.
Voting matters and shareholder proposals
Proxy materials relate to matters requiring shareholder voting as per SEC regulations.
Shareholder rights and capital structure
Filing made under Schedule 14A, ensuring shareholders are informed and able to exercise voting rights.
Partial view of Summaries dataset, powered by Quartr API
Latest events from GoodRx
- Board recommends approval of all proposals at the virtual 2026 Annual Meeting.GDRX
Proxy filing29 Apr 2026 - Sharpened strategy and robust growth in integrated savings and pharma solutions drive margin gains.GDRXMorgan Stanley 22nd Annual Global Healthcare Conference5 Apr 2026
- Pharma Direct revenue surged 41% in 2025, driving growth despite headwinds in other segments.GDRXQ4 202526 Feb 2026
- Q3 2025 saw strong manufacturer solutions growth and resilient financials amid industry headwinds.GDRXQ3 20253 Feb 2026
- Q2 revenue up 6% to $200.6M, Adjusted EBITDA margin 32.6%, with cautious full-year outlook.GDRXQ2 20242 Feb 2026
- Direct contracting, pharma partnerships, and PBM deals drive growth and competitive edge.GDRX2024 Wells Fargo Healthcare Conference22 Jan 2026
- Q3 2024 revenue up 8%, net income $4.0M, and margin expansion driven by pharma solutions.GDRXQ3 202416 Jan 2026
- Direct contracting and manufacturer solutions drive growth and margin gains amid evolving PBM dynamics.GDRXUBS Global Healthcare Conference 202414 Jan 2026
- New Surescripts partnership launches Script Corner for real-time prescription price transparency.GDRX44th Annual J.P. Morgan Healthcare Conference13 Jan 2026